Clene Inc. (CLNN) Dividend History

Clene Inc. (CLNN) is a biotechnology company focused on developing therapies for neurodegenerative diseases and other serious medical conditions. The company specializes in harnessing nanocatalysis technology to create treatments aimed at restoring cellular health and function. Their research primarily targets conditions such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, 84121
Phone: 801-676-9695
Website:

Dividend History

Clene Inc. currently does not pay dividends

Company News

  • Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

    Clene Inc., a clinical-stage biopharmaceutical company, announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings on September 9, 2024.

    GlobeNewswire Inc.
  • Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire

    The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.

    GlobeNewswire Inc.
    Featured Companies: ASPI ATRA AYTU CVKD GDTC IQST LGMK XXII
  • Crude Oil Down 1%; Soligenix Shares Surge - Helen Of Troy (NASDAQ:HELE) - Benzinga

    Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.

    Benzinga
    Featured Companies: HELE QURE SNGX
  • Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

    SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference and host 1x1 investor meetings.

    GlobeNewswire Inc.
  • Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

    SALT LAKE CITY, June 21, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome. Karen Ho, Ph.D., Clene’s vice president of translational medicine, unveiled the data in oral and poster presentations on June 19th at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado. The presentation was titled, “CNM-Au8, a Candidate First-in-Class Nanotherapeutic for Treatment of Rett Syndrome.”

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 19:54:21 UTC